Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Two People Awarded $9 Mln Each In Accutane Case

A New Jersey jury on Friday awarded $9 million each to two people who took the anti-acne drug Accutane, made by Hoffmann-La Roche (RHHBY.PK), and developed bowel disease. Accutane causes inflammatory bowel disease in some individuals.

This was the eighth Accutane case to go to trial in the U.S. To date, plaintiffs have won over $78 million in verdicts against Roche.

The trial lasted almost two months. The jury turned back the claims of two other clients as it found that although Roche failed to warn their prescribing physicians of the dangers of Accutane, they would have been prescribed and taken Accutane anyway.

Click here to receive FREE breaking news email alerts for Roche Holding AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After turning lower over the course of the previous session, stocks are likely to move back to the upside in early trading on Thursday. The major index futures are currently pointing to a sharply higher open for the markets, with the Dow futures up by 136 points. U.K. retail sales declined more-than-expected in September, driven by a sharp contraction in clothing sales. Retail sales fell 0.3 percent in September from a month ago, when it rose 0.4 percent, the Office for National Statistics said Thursday. This was the first drop in four months. Economists had forecast a 0.1 percent drop for September. Food sales recovered in September. The private sector in the eurozone logged a marginal upturn in October helped by an improvement in Germany, while France moved deeper into contraction, flash data from Markit Economics revealed Thursday. The headline flash Markit composite output index rose to 52.2 in October from a 10-month low of 52 in September. The score was forecast to fall to 51.5.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.